The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000687392
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
4/05/2026
Date registered
Help: Date registered
10/06/2026
Date last updated
Help: Date last updated
10/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
10/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
AGIFUS: Focused ultrasound for agitation associated with Alzheimer's disease (AD).
Scientific title
Study of the feasibility and efficacy of focused ultrasound neuromodulation for the treatment of agitation associated with Alzheimer’s disease (AD).
Additional trial identifiers [1] 317186 0
Nil
Universal Trial Number (UTN)
U1111-1340-0984
Trial acronym
AGIFUS
Related trial records

Health condition
Health condition(s) studied:
Alzheimer’s disease 341901 0
Alzheimer’s disease with associated agitation 341902 0
Condition category
Condition code
Neurological 337843 337843 0 0
Alzheimer's disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The UltraThera device (second-generation) is a non-invasive neuromodulation system. It functions by delivering precise, low-intensity ultrasound waves to targeted brain regions. The device is applied to the participant's scalp and utilises image-guided navigation to ensure the acoustic energy is focused accurately on individualised neuroanatomical coordinates. The ultrasound parameters remain constant across all participants receiving verum treatments. Settings are equivalent to those used in our previous study e.g <500 kHz centre frequency, peak negative pressure in free field 1.95 MPa, pulse repetition frequency 10 Hz, pulse length 10 ms, individual sonication duration 6 s depth of treatment 55-85mm, acoustic radiation force index <0.175, ISPPA <22 W/cm2). Treatment depth will be individualised based on MRI. Treatment is administered by clinical investigators. These personnel are specifically trained in the operation of the UltraThera system and the application of image-guided navigation protocols. Delivery is performed face-to-face in an individualised session. The investigator uses the participant’s pre-acquired MRI data to navigate the ultrasound beam to the specific region of interest and pre-specified treatment depth using an MRI of the patient's brain taken before the treatment day. The intervention consists of four treatment sessions. These are delivered once per week for four consecutive weeks. Each session lasts approximately 30 minutes.
Once inducted into the study, participants will undergo baseline assessments including cognitive and behavioural tests and an MRI if they don’t already have a suitable MRI for targeting. All screening, testing, and treatments are conducted within a clinical research facility or hospital. To promote adherence to the intervention and track participant engagement, the following strategies are employed: Actigraphy Monitoring: Participants are required to wear a wrist-worn GeneActiv actigraphy device throughout the trial period. This provides objective data regarding activity patterns and sleep-wake cycles. Clinical Assessments: Feasibility and adherence are monitored via regular assessments and session attendance is logged by the clinical investigator to confirm that the four-week protocol is followed without significant deviation.
Intervention code [1] 333954 0
Treatment: Devices
Description of the comparator or control
Placebo/sham. Participants randomised to the control arm receive a sham intervention designed to maintain the blinding of the participant, the caregiver, and the clinical assessors. Procedure: The sham protocol replicates all clinical procedures used in the active arm. This includes positioning the participant within the UltraThera device and performing the identical image-guided navigation sequence.
Mechanism of Sham: The UltraThera device is operated in a simulated mode. In this setting, the system provides the visual and auditory cues of a standard treatment, but no ultrasound energy is delivered to the brain.
Control group
Placebo

Outcomes
Primary outcome [1] 345302 0
Treatment response rate: defined as a positive Clinical Global Impression-Improvement (CGI-I) agitation assessment (score of 1 or 2).
Timepoint [1] 345302 0
Week 5 after the start of treatment (primary endpoint visit).
Secondary outcome [1] 461219 0
Safety and tolerability.
Timepoint [1] 461219 0
Throughout treatment and at week 5.
Secondary outcome [2] 461220 0
Change in agitation measured by the Cohen-Mansfield Agitation Inventory (CMAI).
Timepoint [2] 461220 0
At week 5 after the start of treatment (compared to baseline).
Secondary outcome [3] 461221 0
Change in broader BPSD (behavioural and psychological symptoms of dementia) symptoms as assessed by the Neuropsychiatric Inventory (NPI).
Timepoint [3] 461221 0
At week 5 after the start of treatment (compared to baseline).
Secondary outcome [4] 461222 0
Change in cognition as measured by the Mini-Mental State Examination (MMSE).
Timepoint [4] 461222 0
At week 5 after the start of treatment (compared to baseline).
Secondary outcome [5] 461223 0
Global symptom severity as measured by Clinical Global Impression-Severity (CGI-S) agitation assessment.
Timepoint [5] 461223 0
At week 5 after the start of treatment (compared to baseline) and at week 12.
Secondary outcome [6] 461519 0
Clinical Global Impression-Improvement (CGI-I) agitation assessment.
Timepoint [6] 461519 0
At week 12 (compared to baseline).

Eligibility
Key inclusion criteria
o Age 50 years or older.
o Probable Alzheimer’s disease diagnosis (NINCDS-ADRDA criteria).
o MMSE score between 5 and 25.
o Clinically significant agitation (NPI Agitation/Aggression) present for at least 2 weeks.
o Stable dose of anti-dementia or psychoactive medications for at least 8 weeks.
o Presence of a live-in caregiver or informant spending at least 15 hours per week with the participant.
o Participant’s legally designated representative must be able to freely give written informed consent; additionally, if, in the clinical judgment of the Principal Investigator, the participant themselves has the mental capacity to provide consent, they will also provide consent.
o Ability to comply with study regimen and provide contact phone number.
o Ability to communicate during procedures.
Minimum age
50 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
o Contraindications to MRI (e.g., metallic implants, claustrophobia) if an MRI is required.
o Any major medical illness (unstable cardiovascular, pulmonary, or renal disease) that could interfere with the study.
o Scalp or skull abnormalities
o History of major psychiatric disorders
o History of drug or alcohol abuse
o Participation in other clinical trials within 90 days from the screening date
o An inability to communicate during a treatment procedure
o A body weight exceeding 200 kg
o Pregnancy or breastfeeding.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation will be concealed using a central randomisation procedure. A designated individual who is not a member of the clinical research team, and who has no role in assessing participant eligibility or performing the interventions, will maintain the master allocation schedule. This schedule is managed via a secure central spreadsheet. Once a participant has been screened and their eligibility is confirmed, the clinical investigator will contact this independent administrator to obtain the treatment assignment for that specific participant.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A simple randomisation procedure is employed to generate the allocation sequence. The sequence is created using computerised randomisation software. Stratified allocation will be employed based on the factor 'symptom severity' as determined by the CGI-S (Clinical Global Impression- Severity scale).
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
The study utilises a randomised, non-comparative design within a Bayesian Efficacy Monitoring framework to evaluate treatment response across two experimental arms, involving a maximum sample size of 60 participants. Participants are assigned in a 10:25:25 ratio to the control and two experimental groups. The primary endpoint is a positive clinical response on the Clinical Global Impression-Improvement scale at Week 5. Bayesian interim analyses occur after 15, 20, and 25 participants in each experimental arm provide endpoint data to evaluate the response rate against a 20% benchmark. Under this framework, an arm may be discontinued for futility if there is a 70% or greater probability that the response rate is below 20%, whereas the treatment is considered promising if the final analysis indicates an 80% or greater probability that the response rate exceeds this threshold. The small control group serves as an informal calibrator to ensure the 20% benchmark remains appropriate for the study population. Simulations indicate that this design provides over 80% power to identify a 40% response rate while maintaining an 80% probability of correctly identifying futility if the true response rate is only 20%.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD

Funding & Sponsors
Funding source category [1] 321767 0
Government body
Name [1] 321767 0
Queensland Health
Country [1] 321767 0
Australia
Funding source category [2] 321769 0
University
Name [2] 321769 0
The University of Queensland
Country [2] 321769 0
Australia
Primary sponsor type
University
Name
The University of Queensland
Address
Country
Australia
Secondary sponsor category [1] 324609 0
None
Name [1] 324609 0
Address [1] 324609 0
Country [1] 324609 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320312 0
Bellberry Human Research Ethics Committee A
Ethics committee address [1] 320312 0
Ethics committee country [1] 320312 0
Australia
Date submitted for ethics approval [1] 320312 0
05/01/2025
Approval date [1] 320312 0
23/06/2025
Ethics approval number [1] 320312 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150050 0
Prof Peter Nestor
Address 150050 0
Mater Misericordiae Ltd Mater Hospital, Raymond Tce South Brisbane QLD 4101 Australia
Country 150050 0
Australia
Phone 150050 0
+61 7 34432505
Fax 150050 0
Email 150050 0
Contact person for public queries
Name 150051 0
Professor Peter Nestor
Address 150051 0
The Queensland Brain Institute QBI Building 79, The University of Queensland, St Lucia QLD 4072, Australia
Country 150051 0
Australia
Phone 150051 0
+61 3346 6300
Fax 150051 0
Email 150051 0
Contact person for scientific queries
Name 150052 0
Professor Jürgen Götz
Address 150052 0
The Queensland Brain Institute QBI Building 79, The University of Queensland, St Lucia QLD 4072, Australia
Country 150052 0
Australia
Phone 150052 0
+61 7 3346 6300
Fax 150052 0
Email 150052 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.